卡介苗接种作为对抗SARS-CoV-2的防御(BADAS):一项通过增强训练免疫保护美国医护人员随机对照试验
BADAS 是一项安慰剂对照适应性多中心随机对照试验,计划纳入1800名高风险个体(含医护人员),按1:1随机接受皮内卡介苗或生理盐水安慰剂,追踪SARS-CoV-2感染及严重程度并检测免疫学标志物,多数随访6个月,认知亚研究2年。
要点
- 皮内接种卡介苗或生理盐水安慰剂,两组按1:1随机分配。
- 计划纳入1800名高风险个体,含医护人员、共病患者及少数族裔等。
- 多数个体随访6个月,可延长6个月,认知亚研究持续2年。
核心结论
- 预期该试验可在人群水平评估卡介苗接种对高风险医护人员SARS-CoV-2感染临床病程的影响,并为疫情期间政策制定提供信息。
研究设计与样本
- 安慰剂对照适应性多中心随机对照试验,计划纳入1800名高风险个体,按1:1随机分配至皮内卡介苗组或生理盐水安慰剂组。
主要发现
- 原文未报告试验结果。
关键数值与推荐
- 高风险个体包括共病患者(高血压、糖尿病、肥胖、反应性气道疾病、吸烟者)、种族和族裔少数群体、老年人、教师、警察、餐厅服务员、配送人员、医护人员及急救人员。
- 多数个体随访6个月,可选择延长6个月,认知亚研究持续2年。
- 采用Kaplan-Meier曲线比较组间,并使用Cox比例风险模型报告风险比和P值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A large epidemic, such as that observed with SARS-CoV-2, seriously challenges available hospital capacity, and this would be augmented by infection of healthcare workers (HCW). Bacillus Calmette-Guérin (BCG) is a vaccine against tuberculosis, with protective non-specific effects against other respiratory tract infections in vitro and in vivo. Preliminary analyses suggest that regions of the world with existing BCG vaccination programs have lower incidence and mortality from COVID-19. We hypothesize that BCG vaccination can reduce SARS-CoV-2 infection and disease severity. METHODS: This will be a placebo-controlled adaptive multi-center randomized controlled trial. A total of 1800 individuals considered to be at high risk, including those with comorbidities (hypertension, diabetes, obesity, reactive airway disease, smokers), racial and ethnic minorities, elderly, teachers, police, restaurant wait-staff, delivery personnel, health care workers who are defined as personnel working in a healthcare setting, at a hospital, medical center or clinic (veterinary, dental, ophthalmology), and first responders (paramedics, firefighters, or law enforcement), will be randomly assigned to two treatment groups. The treatment groups will receive intradermal administration of BCG vaccine or placebo (saline) with groups at a 1:1 ratio. Individuals will be tracked for evidence of SARS-CoV-2 infection and severity as well as obtaining whole blood to track immunological markers, and a sub-study will include cognitive function and brain imaging. The majority of individuals will be followed for 6 months, with an option to extend for another 6 months, and the cognitive sub-study duration is 2 years. We will plot Kaplan-Meier curves that will be plotted comparing groups and hazard ratios and p-values reported using Cox proportional hazard models. DISCUSSION: It is expected this trial will allow evaluation of the effects of BCG vaccination at a population level in high-risk healthcare individuals through a mitigated clinical course of SARS-CoV-2 infection and inform policy making during the ongoing epidemic. TRIAL REGISTRATION: ClinicalTrials.gov NCT04348370. Registered on April 16, 2020.
引用
- DiNardo AR, Arditi M, Kamat AM, et al. Bacillus Calmette-Guérin vaccination as defense against SARS-CoV-2 (BADAS): a randomized controlled trial to protect healthcare workers in the USA by enhanced trained immune responses. Trials. 2023. PMID: 37794431. doi:10.1186/s13063-023-07662-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。